Xencor (XNCR) Net Cash Flow (2013 - 2026)
Xencor (XNCR) posted quarterly Net Cash Flow of -$40.0 million for Q1 2026, down 2969.92% year-over-year from $1.4 million in Q1 2025, and down 255.14% quarter-over-quarter from $25.8 million in Q4 2025.
Xencor (XNCR) Net Cash Flow (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Net Cash Flow for 14 consecutive years, with -$40.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 2969.92% year-over-year to -$40.0 million; the TTM figure through Mar 2026 stood at -$25.6 million (down 399.64% YoY), while the FY2025 annual figure was $13.1 million, up 201.49% from the prior year.
- Net Cash Flow declined to -$40.0 million in Q1 2026 per XNCR's latest filing, from $25.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $25.8 million in Q4 2025 and bottomed at -$65.2 million in Q1 2022.
- Historically, Net Cash Flow has averaged -$7.6 million across 5 years, with a median of -$264000.0 in 2024.
- Annual changes were most pronounced in 2025 — Net Cash Flow soared 1906.44% — and 2026, when it slumped 2969.92%.
- Xencor's Net Cash Flow stood at $1.3 million in 2022, then declined by 17.78% to $1.1 million in 2023, then jumped by 1018.6% to $11.8 million in 2024, then soared by 117.65% to $25.8 million in 2025, then slumped by 255.14% to -$40.0 million in 2026.
- Business Quant data shows XNCR's Net Cash Flow at -$40.0 million in Q1 2026, $25.8 million in Q4 2025, and -$16.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 30.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.49 Mn |
| Jun 30, 2026 | 30.49 Mn |
| Mar 31, 2026 | -40.00 Mn |
| Mar 31, 2026 | -40.00 Mn |
| Dec 31, 2025 | 25.78 Mn |
| Dec 31, 2025 | 25.78 Mn |
| Sep 30, 2025 | -16.15 Mn |
| Sep 30, 2025 | -16.15 Mn |
| Jun 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 4.77 Mn |
| Mar 31, 2025 | -1.30 Mn |
| Mar 31, 2025 | -1.30 Mn |
| Dec 31, 2024 | 11.85 Mn |
| Dec 31, 2024 | 11.85 Mn |
| Sep 30, 2024 | -1.74 Mn |
| Sep 30, 2024 | -1.74 Mn |
| Jun 30, 2024 | -264,000.00 |
| Jun 30, 2024 | -264,000.00 |
| Mar 31, 2024 | -22.75 Mn |
| Mar 31, 2024 | -22.75 Mn |